Stephanie A. Lodise Ph.D.

Partner

Philadelphia
T +1.215.564.8918
F +1.215.568.3439

"Stephanie Lodise offers impressive experience advising pharmaceutical companies on patent portfolio management and development." 

— Chambers USA 2021

Overview

Stephanie Lodise is co-leader of the firm’s Biotechnology, Chemical and Pharmaceutical Team and a patent attorney with more than 15 years of experience in securing, expanding and maintaining exclusivity for pharmaceuticals in the U.S. and abroad. She focuses on building patent portfolios for both new and re-purposed small molecules, reinforcing mature patent portfolios, analyzing freedom-to-market issues, managing patent office administrative impediments, navigating patent landscapes and developing patent protection for products subject to Hatch-Waxman litigation.

Stephanie's practice focuses on all phases of highly sophisticated patent prosecution and analysis for pharmaceutical and material science clients. Large patent portfolios require adroit management, and Stephanie demonstrates her proficiency by directing the prosecution of complex portfolios both in the U.S. and internationally. Her scientific acumen, advocacy and pragmatism are instrumental in obtaining and maintaining key patent coverage for commercialized and licensed technologies. As one of the few patent lawyers in the country with a Ph.D. in synthetic organic chemistry, as well as experience as a research chemist at a major pharmaceutical company, Stephanie's skills in small molecule design, synthesis, formulation and use are highly valued among many life sciences clients.

Select Experience

  • Prosecutes, manages and advises on U.S. and international patent portfolios encompassing oncological, antiviral, antibacterial, and radio-labeled pharmaceuticals.
  • Prosecutes, manages and advises on U.S. and international patent portfolios encompassing isotopically-labeled small molecules.
  • Prosecutes, manages and advises on U.S. and international patent portfolios encompassing drug repositioning technologies.
More »

Experience

  • Prosecutes, manages and advises on U.S. and international patent portfolios encompassing oncological, antiviral, antibacterial and radio-labeled pharmaceuticals.
  • Prosecutes, manages and advises on U.S. and international patent portfolios encompassing isotopically-labeled small molecules.
  • Prosecutes, manages and advises on U.S. and international patent portfolios encompassing drug repositioning technologies.
  • Prosecutes reissue and ex parte reexamination applications for small molecule pharmaceutical compounds.
  • Advises on patent portfolio development and preservation for commercially marketed pharmaceuticals, including Amyvid®, Austedo®, Bendeka®, Erleada®, Impoyz®, Olysio®, Prezista®, and Treanda®.
  • Prepares and argues appeals to the Patent Trial and Appeal Board. 
  • Advises on patent portfolio development and preservation for 505(b)(2) products.
  • Creates and develops patent portfolios for pharmaceutical startup companies, creating assets critical in obtaining capital investments.
  • Provides analysis and advice regarding patent landscapes in various therapeutic areas.
  • Provides advice and performs freedom-to-operate assessments in support of due diligence analyses for small molecule pharmaceuticals, medical devices and polymers
  • Provides advice and performs freedom-to-operate assessments in support of due diligence analyses for dermatological and transdermal compositions.
  • Advises on and prepares applications for Patent Term Extensions.
  • Advises on Orange Book listings.
  • Provides advice on the impact of the judicially created doctrine of obviousness-type double patenting on pharmaceutical patent portfolios.

Recognitions and Memberships

Recognitions

  • The Legal 500 United States
    • Intellectual Property: Patents - Prosecution (Including Reexamination and Post-Grant Proceedings) (2022)
  • Regulatory Affairs Certificate: Medical Devices and Pharmaceuticals
  • Chambers USA: Intellectual Property in Pennsylvania (2020 to 2022)
    • Band 4 (2020 to 2022)
  • Pennsylvania Super Lawyers "Rising Star" (2011 to 2012; 2014 to 2015)
  • Co-Recipient of the 2011 Thomas Alva Edison Patent Award in the Pharmaceuticals category

Memberships

  • Regulatory Affairs Professionals Society
  • ChIPs, Philadelphia Chapter

Industries

Prior Positions

  • Philadelphia Intellectual Property Association: Board of Governors (2008 to 2010)

Admissions

  • U.S. District Court, Eastern District of Pennsylvania
  • U.S. District Court, District of New Jersey
  • U.S. Patent and Trademark Office, Registration No. 51,430
  • New Jersey
  • Pennsylvania

Education

  • J.D., Rutgers University School of Law, Camden, 2005, with highest honors, graduated first in class; Notes and Casenotes Editor, Rutgers Law Journal
  • Ph.D., Organic Chemistry, University of Pennsylvania, 2000; (Progress toward the total synthesis of tedanolide and 13-deoxytedanolide, Prof. Amos B. Smith, III); recipient of American Chemical Society Division of Organic Chemistry Graduate Fellowship (1998 to 1999)
  • B.A., Chemistry, Rutgers University, 1995, with honors, Phi Beta Kappa

Blog

In The Blogs

Previous Next
IP Intelligence: Insight on Intellectual Property
Podcast: Navigating the Fine Line Between Obviousness and Obviousness-Type Double Patenting
By Stephanie A. Lodise Ph.D., Tracy U. Palovich Ph.D.
December 15, 2021
Partner Stephanie Lodise and Patent Agent Tracy Palovich, Ph.D., break down the differences between obviousness rejections and obviousness-type double patenting rejections. They then provide important prosecution strategies how to respond...
Read More ->